← Leaderboards
Michael Ohlmeyer
Icahn School Of Medicine At Mount Sinai
$4,746,622
Attributed
$5,767,278
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,767,278 · 6
By mechanism
R44$2,516,671 · 1
R33$1,248,901 · 1
R43$854,295 · 2
R21$792,411 · 1
N43$355,000 · 1
Top collaborators
- Ming-Ming Zhou5 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Nathan E Goldstein$9,630,744
- Syed S Mujtaba$1,397,337
- Michal Schnaider Beeri$14,706,707
- Cesar Llogari Moreno$105,855
- Bryan Thomas Denny$2,259,305
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposLeadNovel TherapeuticsDoseOralIn VitroBiological AvailabilityStructureIn VivoPenetrationScale UpSafetySeriesRattusPharmaceutical PreparationsBehavioralSmall MoleculeProgramsBrainPharmaceutical ChemistryMediatingLifeRouteEvaluation
Grant awards (10)
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics$828,594
R44 · FY2025 · AG · contact PI
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics$1,688,077
R44 · FY2024 · AG · contact PI
SBIR CONCEPT AWARD - THERAPEUTICS - SULFONYL-UREA AND SULFONAMIDE PP2A ACTIVATORS AS MYCN AMPLIFIED NEUROBLASTOMA (NBL) THERAPEUTICS$355,000
N43 · FY2024 · CA · contact PI
Direct Activation of PP2A as a Novel Approach to Group-3 Medulloblastoma Therapy$406,500
R43 · FY2022 · CA · contact PI
Direct activators of protein phosphatase 2A (PP2A) as novel Alzheimer's Disease (AD) therapeutics$447,795
R43 · FY2020 · AG · contact PI
Small Molecule Libraries Targeted to CBP and Attenuation AfosB Expression$421,926
R33 · FY2014 · DA
Small Molecule Libraries Targeted to CBP and Attenuation AfosB Expression$405,049
R33 · FY2013 · DA · contact PI
Small Molecule Libraries Targeted to CBP and Attenuation AfosB Expression$421,926
R33 · FY2012 · DA · contact PI
Small Molecule Libraries Targeted to CBP and Attenuation AfosB Expression$411,036
R21 · FY2011 · DA · contact PI
Small Molecule Libraries Targeted to CBP and Attenuation AfosB Expression$381,375
R21 · FY2010 · DA · contact PI